Literature DB >> 29792364

Current evidence in the stability of medicines in dose administration aids: implications for patient safety.

Estela R García1, Stefanie Thalhauser1, Hèctor R Loscertales1, Pilar Modamio1, Cecilia F Lastra1, Eduardo L Mariño1.   

Abstract

INTRODUCTION: As the elderly population and polypharmacy are increasing, it is predicted that interventions to enhance medication adherence, as dose administration aids (DAA), will grow. One of the limitations of repackaging medicines into DAA is to assure the stability of medicines, and, therefore, their quality, efficacy and safety. AREAS COVERED: This article collects and summarises data of all the stability studies of repackaged medicines into DAAs. Computerized search in databases: PubMed, Google Scholar, SciELO, and reference texts related to the field (keywords: drug stability, DAAs, compliance aids, and repackaging), open access databases and guidelines. Also, it provides recommendations on the suitability of repackaging and compares them with those established. EXPERT OPINION: Since medicines are removed from primary package, their stability can be compromised due to psychochemical characteristics of the drug substance and product, the dosage form, the type of DAA selected, the co-storage and splitting, the repackaging conditions, and the conditions of storage. This review reflects the need of more standardized stability studies to guarantee the quality of repackaged medicines. In addition, the importance of them to support the pharmacist to make the best decisions in order to maximize outcomes and minimize risks related to patients' medication when repackaging it.

Entities:  

Keywords:  Dose administration aids; drug stability; medication adherence; patient safety; repackaging

Mesh:

Substances:

Year:  2018        PMID: 29792364     DOI: 10.1080/17425247.2018.1480610

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  2 in total

1.  Adverse drug events observed with 150 mg versus 300 mg secukinumab for the treatment of moderate to severe plaque psoriasis: A systematic review and meta-analysis.

Authors:  Li Zhang; Hua Yang; Qihong Chen; Jing Zhao
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

2.  Telmisartan Tablets Repackaged into Dose Administration Aids: Physicochemical Stability under Tropical Conditions.

Authors:  Anthony P Ma; Sherryl G Robertson; Beverley D Glass
Journal:  Pharmaceutics       Date:  2022-08-11       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.